Contact WAO | e-News Sign Up | Site Map | Home  
World Allergy Organization
WAO's mission: To be a global resource and advocate in the field of allergy, advancing excellence in clinical care through education, research and training as a world-wide alliance of allergy and clinical immunology societies.

Book review may be available in other languages

WAO Medical Book Review

Posted: May 2012

Current Concepts in Clinical Management and Long Term Control of Atopic Dermatitis: Focus on Primecrolimus Cream 1%
Edited by Seth J. Orlow
Supplement Issue: Dermatology 2007, Vol. 215, Suppl. 1
2007 Karger (Basil, Switzerland)
ISBN: 978-3-8055-8323-7
e-ISBN: 978-3-8055-8131-8

Retail: $34 US
Available from Karger

Reviewer
Virginia Bellido-Linares, MD
Allergy Unit
Virgen Macarena Hospital
Seville, Spain

Description
This paperback book is a good collection of articles focus on primecrolimus cream 1% treatment in patients who suffer from atopic dermatitis. It contains a synopsis at the beginning and four full articles.

Purpose
These articles are centered on clinical management of atopic eczema in infants and children as well as adults, focusing on safety and tolerability of primecrolimus in the various patient populations. The last article describes new indications of topical calcineurin inhibitors.

Audience
The book may be very interesting to allergists, dermatologists and general practitioners interested in atopic eczema. The writing style and graphics make this book easy to read and understand.

Content/Features
The first two articles focus on the role of primecrolimus cream 1% in adults and children with atopic eczema. Clinical outcomes of numerous trials comparing primecrolimus, tacrolimus and corticosteroids are summarized in the second section. A third article summarizes safety and tolerability of primecrolimus cream in clinical trials and in post-marketing surveillance.

The authors conclude that on the basis of published trials, there is sufficient evidence that both calcineurin inhibitors are safe and well tolerated in treatment longer than 24 months, and no cases of malignancies have been reported.

The final article outlines potential indications of calcineurin inhibitors. Their mode of action suggests that they represent a very good alternative to corticosteroids, not only for atopic eczema but for a number of inflammatory diseases particularly on sensitive areas such as face, neck and genital skin. Efficacy has been demonstrated for flexural psoriasis, seborrhoeic, contact and hand eczema. New data support efficacy in lichen planus, facial lupus erythematosus, autoimmune bullous dermatosis, and vitiligo.

Assessment
This book provides a broad view on management of atopic eczema with an emphasis on the place of calcineurin inhibitors in the management plan. It also outlines potential uses for this class of drugs in other cutaneous disorders.